Synlogic Overview

  • Status
  • Public

  • Employees
  • 87

Employees

  • Stock Symbol
  • SYBX

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $0.98
  • (As of Wednesday Closing)

Synlogic General Information

Description

Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. The pipeline drug candidates includes: labafenogene marselecobac (SYNB1934); SYNB1353 Classical Homocystinuria (HCU); SYNB8802 Enteric Hyperoxaluria; and SYNB2081 Gout. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one operating segment: Discovery and development of Synthetic Biotics.

Contact Information

Formerly Known As
TMC Therapeutics
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • PO Box 30
  • Winchester, MA 01890
  • United States
+1 (617)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
OTCM
Vertical(s)
Corporate Office
  • PO Box 30
  • Winchester, MA 01890
  • United States
+1 (617)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Synlogic Stock Performance

As of 18-Nov-2026, Synlogic’s stock price is $0.98. Its current market cap is $12M with 12.2M shares.

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.98 $1.10 $0.54 - $1.73 $12M 12.2M 18.4K $0.42

Synlogic Financials Summary

As of 30-Sep-2026, Synlogic has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 536 (2,488) (3,014) 20,163
Revenue 0 0 8 3,371
EBITDA (2,737) (1,700) (24,432) (61,769)
Net Income (2,226) (1,005) (23,359) (61,273)
Total Assets 11,849 15,447 19,826 75,550
Total Debt 0 0 0 17,275
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Synlogic Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Synlogic‘s full profile, request access.

Request a free trial

Synlogic Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Synlogic‘s full profile, request access.

Request a free trial

Synlogic Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a program in phenylketonuria (PKU)
Drug Discovery
Winchester, MA
87 As of 2025

San Diego, CA
 

San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Synlogic Competitors (103)

One of Synlogic’s 103 competitors is BioAtla, a Formerly VC-backed company based in San Diego, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
BioAtla Formerly VC-backed San Diego, CA
Vir Biotechnology Formerly VC-backed San Francisco, CA
AbCellera Biologics Formerly VC-backed Vancouver, Canada
Aclaris Therapeutics Formerly VC-backed Wayne, PA
Clearside Biomedical Formerly VC-backed Alpharetta, GA
You’re viewing 5 of 103 competitors. Get the full list »

Synlogic Patents

Synlogic Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2024298173-A1 Recombinant bacteria engineered to treat diseases associated with methionine metabolism and methods of use thereof Pending 26-Jul-2023
EP-4750891-A1 Recombinant bacteria engineered to treat diseases associated with methionine metabolism and methods of use thereof Pending 26-Jul-2023
US-20260226448-A1 Recombinant bacteria engineered to treat diseases associated with methionine metabolism and methods of use thereof Pending 26-Jul-2023
WO-2025024642-A1 Recombinant bacteria engineered to treat diseases associated with methionine metabolism and methods of use thereof Inactive 26-Jul-2023
JP-2026528174-A Recombinant bacteria engineered to treat diseases related to methionine metabolism and their use. Pending 26-Jul-2023 C12N15/70
To view Synlogic’s complete patent history, request access »

Synlogic Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Synlogic Acquisitions (2)

Synlogic’s most recent deal was a Reverse Merger with Caldera Therapeutics. The deal was made on 29-Jul-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Caldera Therapeutics 29-Jul-2026 Reverse Merger Drug Discovery
Mirna Therapeutics 28-Aug-2017 Merger/Acquisition Biotechnology
To view Synlogic’s complete acquisitions history, request access »

Synlogic ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Synlogic’s complete esg history, request access »

Synlogic Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Synlogic Ibdco Cambridge, MA 2017

Synlogic FAQs

  • Where is Synlogic headquartered?

    Synlogic is headquartered in Winchester, MA.

  • What is the size of Synlogic?

    Synlogic has 87 total employees.

  • What industry is Synlogic in?

    Synlogic’s primary industry is Drug Discovery.

  • Is Synlogic a private or public company?

    Synlogic is a Public company.

  • What is Synlogic’s stock symbol?

    The ticker symbol for Synlogic is SYBX.

  • What is the current stock price of Synlogic?

    As of 18-Nov-2026 the stock price of Synlogic is $0.98.

  • What is the current market cap of Synlogic?

    The current market capitalization of Synlogic is $12M.

  • Who are Synlogic’s competitors?

    BioAtla, Vir Biotechnology, AbCellera Biologics, Aclaris Therapeutics, and Clearside Biomedical are some of the 103 competitors of Synlogic.

  • What is Synlogic’s annual earnings per share (EPS)?

    Synlogic’s EPS for 12 months was $0.42.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process